Sharps Technology Enters Into 5-Year Sales Agreement With Strategic U.S. Medical Products Company Creating +$50M In New Revenue For EU Facility, Definitive Agreement Sells Out The 10mL SoloGard Production Capacity At Sharps' Manufacturing Site
Portfolio Pulse from Benzinga Newsdesk
Sharps Technology, Inc. (NASDAQ: STSS) has entered into a 5-year sales agreement with a U.S. medical products company, generating over $50M in new revenue for its EU facility. The agreement sells out the 10mL SoloGard production capacity and necessitates expansion to meet future demand.
July 25, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sharps Technology has secured a 5-year sales agreement with a U.S. medical products company, generating over $50M in new revenue and selling out the 10mL SoloGard production capacity. This will drive the need for expansion at their EU facility.
The 5-year sales agreement with a U.S. medical products company will significantly boost Sharps Technology's revenue and fully utilize their current production capacity. This positive development is likely to drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100